Financial Ratios

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

NSE : BIOFILCHEMBSE : 524396ISIN CODE : INE829A01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE60.36-0.23 (-0.38 %)
PREV CLOSE ( ) 60.59
OPEN PRICE ( ) 61.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 7865
TODAY'S LOW / HIGH ( )59.20 62.30
52 WK LOW / HIGH ( )40.66 78.8
NSE60.600.3 (+0.5 %)
PREV CLOSE( ) 60.30
OPEN PRICE ( ) 60.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 23696
TODAY'S LOW / HIGH( ) 60.00 62.90
52 WK LOW / HIGH ( )40.35 79
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)0.340.430.760.740.30
   CEPS(Rs)0.610.691.020.990.52
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)10.6310.359.919.158.39
   Tax Rate(%)29.3331.1935.3117.5519.39
Margin Ratios
   Core EBITDA Margin(%)3.895.954.476.144.43
   EBIT Margin(%)2.784.725.565.343.29
   Pre Tax Margin(%)2.644.535.374.932.59
   PAT Margin (%)1.873.123.474.072.09
   Cash Profit Margin (%)3.295.034.625.443.66
Performance Ratios
   ROA(%)2.242.693.283.631.99
   ROE(%)3.284.248.018.463.60
   ROCE(%)4.766.2312.1810.125.06
   Asset Turnover(x)1.200.860.950.890.96
   Sales/Fixed Asset(x)2.581.933.112.622.19
   Working Capital/Sales(x)3.462.865.336.206.89
Efficiency Ratios
   Fixed Capital/Sales(x)0.390.520.320.380.46
   Receivable days168.17198.88239.55256.53197.31
   Inventory Days15.2345.9730.8217.7217.48
   Payable days88.15154.25235.08248.78161.80
Valuation Parameters
   PER(x)120.33134.6786.069.9822.30
   PCE(x)68.1583.5464.627.4512.69
   Price/Book(x)3.905.596.620.810.79
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)2.264.222.990.440.53
   EV/Core EBITDA(x)53.7163.6444.536.5110.90
   EV/EBIT(x)81.3089.4253.768.1816.13
   EV/CE(x)2.165.043.210.310.51
   M Cap / Sales2.254.202.990.410.47
Growth Ratio
   Net Sales Growth(%)34.19-37.3920.4128.3787.12
   Core EBITDA Growth(%)-14.73-38.1820.2677.338.49
   EBIT Growth(%)-20.84-46.8825.24108.802.59
   PAT Growth(%)-19.76-43.742.83150.302.46
   EPS Growth(%)-19.76-43.732.83150.302.46
Financial Stability Ratios
   Total Debt/Equity(x)0.030.030.030.080.12
   Current Ratio(x)1.636.231.401.171.32
   Quick Ratio(x)1.545.371.141.111.20
   Interest Cover(x)19.6626.0029.1812.964.70
   Total Debt/Mcap(x)0.010.000.000.100.15

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.